share_log

Press Release: Fidmi Medical Launches U.S. Sales of Novel Low-Profile PEG Device and Raises $2.2 Million

Dow Jones Newswires ·  Oct 11, 2021 08:04

Press Release: Fidmi Medical Launches U.S. Sales of Novel Low-Profile PEG Device and Raises $2.2 Million

Fidmi Medical Launches U.S. Sales of Novel Low-Profile PEG Device and Raises $2.2 Million

PR Newswire

CAESAREA, Israel, Oct. 11, 2021

CAESAREA, Israel, Oct. 11, 2021 /PRNewswire/ -- Fidmi Medical Ltd. (www.fidmimedical.com) has announced completion of a $2.2 million financing round and launched its FDA-cleared low-profile Percutaneous Endoscopic Gastrostomy (PEG) device in the U.S. Investors in the round include leading medical technology company Micro-Tech (Nanjing) Co., Ltd. (688029: Shanghai), The Trendlines Group (www.trendlines.com), (SGX: 42T) (OTCQX: TRNLY), and Agriline. Micro-Tech has been named Fidmi's exclusive distributor in the U.S. (www.mtendoscopy.com) and China.

Gastrostomy tubes, which help patients receive long-term nutritional support, are typically placed endoscopically and are replaced every 3-6 months. Complications such as clogging and dislodgement are common, resulting in inadequate nutrition and medication delivery, numerous tube replacements, and hospitalizations, all at substantial cost to patients and the health care system.

Within this $800 million market, Fidmi Medical's innovative low-profile gastrostomy system can be utilized for both initial placement and replacement and is more durable and comfortable for patients. Fidmi's improved low-profile gastrostomy tube has a replaceable inner tube that can easily be changed by patients without the assistance of medical professionals and a highly stable internal bumper that is resistant to accidental dislodgement. These features are expected to result in fewer complications, reducing healthcare costs for payers and healthcare systems. The Fidmi PEGs will provide a substantial improvement in quality of life for patients and their caregivers.

Fidmi Medical CEO Shahar Millis remarked, "We are truly excited to embark on the market entry phase for Fidmi. With FDA clearance and strategic collaboration with Micro-Tech, a leader in this field, we are well-positioned to make a real difference for people requiring long-term nutritional support."

"Together, we saw the opportunity to distribute a device that positively impacts patients and helps them get back to living their lives. We worked quickly to align on a distribution plan that allows the system to be accessible by more physicians -- meeting their needs for more efficient and higher quality patient care, all while tangibly reducing the cost," said Chris Li, President of Micro-Tech Endoscopy USA. "We are proud to partner with Fidmi and applaud their success in improving patient quality of life."

About Fidmi Medical

Fidmi Medical is an Israeli medical device company dedicated to developing enhanced feeding devices that offer easy insertion, replacement, and removal. Fidmi is a portfolio company of The Trendlines Group.

About Micro-Tech Endoscopy USA

Micro-Tech Endoscopy is focused on creating top-quality products for endoscopic diagnosis, and therapeutic medical devices that allow physicians to provide the highest level of care. By partnering with doctors dedicated to innovation, Micro-Tech is committed to bringing better devices to market, with unparalleled speed, at an economical price, and without the burden of contracts.

Contact:

Fidmi Medical

Shahar Millis, CEO, Fidmi Medical Ltd.

info@fidmimedical.com

+972-77-3628362

Micro-Tech Endoscopy USA, Inc.

Stephanie Reynolds / Emmie McMinn

stephanie.reynolds@trailrunnerint.com

emmie.mcminn@trailrunnerint.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fidmi-medical-launches-us-sales-of-novel-low-profile-peg-device-and-raises-2-2-million-301396871.html

SOURCE Fidmi Medical Ltd.

/Web site: https://www.fidmimedical.com

(END) Dow Jones Newswires

October 11, 2021 08:00 ET (12:00 GMT)

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment